

**RECOMBINANT PROTEOLYTIC TRYPTASES,  
ACTIVE SITE MUTANTS THEREOF,  
AND METHODS OF MAKING SAME**

Andrew L. Niles  
Mark A. Maffitt  
Mary Haak-Frendscho

This is a Continuation-In-Part of application Ser. No. 09/079,970,  
filed April 15, 1998.

FIELD OF THE INVENTION

5 The invention is directed to a method of making an enzymatically-  
active recombinant proteolytic tryptase in a genetically-engineered microbial  
host, expression constructs encoding the enzymatically-active proteolytic  
tryptase, and genetically-engineered eukaryotes which express the  
enzymatically-active recombinant proteolytic tryptase. The invention is also  
directed to a method of making an active site mutant of a recombinant  
10 proteolytic tryptase in a genetically-engineered microbial host, expression  
constructs encoding the mutated proteolytic tryptase lacking enzymatic  
activity due to the active site mutation, and genetically-engineered  
eukaryotes which express the mutated recombinant proteolytic tryptase  
having the active site mutation.

BIBLIOGRAPHY

15 Complete bibliographic citations to the references noted herein are  
included in the Bibliography section, immediately preceding the Sequence  
Listing.

## DESCRIPTION OF THE RELATED ART

5 Mast cell  $\beta$ -tryptase is a neutral serine protease of presently unknown biological function *in vivo*. However, it has been implicated in asthma, angiogenesis, and tissue remodeling. It constitutes up to 20% w/v of the total granule protein of mast cells.  $\beta$ -tryptase is selectively stored in mast cell granules and is released upon mast cell degranulation. Because  $\beta$ -tryptase is unique to mast cells, it has gained favor as a specific marker of mast cell-mediated pathology. For a complete discussion regarding mast cell heterogeneity, structure, and mediators, see *Nilsson and Schwartz* (1994).  
10

In asthma, mast cells have long been implicated in the acute immunological reactions that occur immediately following allergen challenge, see, for example, *Holgate and Church* (1992). In an allergic sheep model, *J.M. Clark et al.* (1995) have shown that tryptase has a role as an important mediator in antigen-induced airway responses.  
15

A number of proteins have been reported to be substrates for tryptase cleavage *in vitro*, including the  $\alpha$ - and  $\beta$ -chains of fibrinogen, see *Schwartz et al.* (1985). Tryptase cleaves fibrinogen into fragments that lack clotting activity, potentially acting as an anticoagulant at sites of mast cell degranulation.  
20

Purified native human  $\beta$ -tryptase is a tetrameric endoprotease of approximately 134 kDa. Each of the four subunits is approximately 31 to 34 kDa in size. As noted in *Schwartz* (1995), human tryptase was first purified to apparent homogeneity from dispersed and enriched lung mast cells in 1981. However, further research has shown that there are at least two different types, or groups, of mammalian tryptase: a proteolytic tryptase and a non-proteolytic tryptase. The proteolytic tryptases, in their protryptase form, are able to be cleaved to yield active tryptases. Cleavable proteolytic tryptase includes  $\beta$ -tryptases,  $\beta$ -like tryptases, and  
25

transmembrane tryptases.  $\beta$ -tryptases can be further divided into two predominant  $\beta$  isoforms:  $\beta$ -I and  $\beta$ -II. The  $\beta$ -I isoform has previously been referred to as skin tryptase, and the  $\beta$ -II isoform has previously been referred to as lung tryptase. This new nomenclature is used herein.

5 In contrast to the cleavable proteolytic tryptase, a second type of tryptase, non-proteolytic tryptase, is not able to be cleaved. Thus, the non-proteolytic tryptase is not enzymatically active. The non-proteolytic tryptase includes  $\alpha$ -tryptase. *Huang et al.* (1999) attribute the cleavability in proteolytic tryptase to amino acids R-V at amino acids -3 and -2 from  
10 amino acid 1 (the first amino acid of the cleaved proteolytic tryptase). R-V is present in  $\beta$ -tryptase, whereas it is absent in  $\alpha$ -tryptase. Moreover, the proteolytic and non-proteolytic tryptase are from distinct genes.

Human tryptase is conventionally isolated from cadaveric lung tissue, as described by *Smith et al.* (1984).

15 A number of researchers have reported cloning cDNAs which encode human tryptase, see *Miller et al.* (1990), *Vanderslice et al.* (1990), and *Blom and Hellman* (1993), as well as rat mast cell tryptase, see *Ide et al.* (1995).

20 However, previous attempts at expressing human tryptase, particularly expressing active tryptase, using either bacterial or baculovirus expression systems are plagued with a myriad of problems, including protein folding problems that result in a lack of enzymatic activity. These failures are due, at least in part, to the fact that the tryptase enzyme is extensively modified post-translationally to yield the active form of the enzyme. Consequently, the specific activity of a recombinant tryptase  
25 produced in a prokaryote would be expected to be low due to the lack of post-translational glycosylation. As a further consequence, previous attempts to produce enzymatically-active recombinant human tryptase have proven to be far less than ideal because the methods require post-expression

chemical modifications and subsequent purification to activate the enzyme precursor.

For instance, *Sakai et al.* (1996) report the expression and purification of recombinant human  $\alpha$ -tryptase and  $\beta$ -tryptase precursors in a baculovirus system. However, the tryptase precursors formed are inactive.

Regarding the use of methylotrophic yeasts (e.g., *Hansenula polymorpha*, *Kluyveromyces lactis*, *Pichia pastoris*, *Schizosaccharomyces pombe*, *Schwanniomyces occidentalis* and *Yarrowia lipolytica*) as hosts for the production of heterologous proteins, the characteristics of these organisms and their suitability for such use has been extensively reviewed in the relevant literature. See, for example, *Faber et al.* (1995) and *Buckholz and Gleeson* (1991).

*Chan et al.* (1999) have cloned protryptase in a methylotrophic yeast. The expressed product of *Chan et al.* is a protryptase monomer that must be exogenously processed to form an active tetrameric tryptase. This conversion requires an additional two column purification method, including a heparin- and dipeptidyl peptidase I-dependent activation step. These exogenous processing steps result in very low expression levels, large losses in the amount of enzyme at each step, and a very low final yield of purified enzyme.

Previous cloned tryptases do not include the cleavage site. Thus, the cloned tryptase lacked the RV at amino acids -3 and -2. Therefore, these cloned tryptases do not cleave. Because these previous tryptase systems do not cleave, the previous tryptases do not spontaneously form enzymatically-active tetramers.

The active sites of proteolytic tryptases have not been previously determined. While amino acids 44, 91, and 194 are conserved in proteolytic tryptases, and implicated to exist in the enzymatic active site,

there has been no previous demonstration that these three amino acids are required for activity.

*Huang et al.* (1999) have mutated  $\alpha$ -tryptase and expressed it in insect cells to determine the importance of residue 215, which is in one of the surface loops that forms the substrate-binding cleft of  $\alpha$ -tryptase. Expression of heterologous  $\alpha$ -tryptase in insect cells by *Huang et al.* requires several *ex vivo* post-translational steps to activate the protein.

### SUMMARY OF THE INVENTION

Expression of tryptase in yeast provides the only expression system in which an enzymatically-active proteolytic tryptase, (e.g.,  $\beta$ -I,  $\beta$ -II,  $\beta$ -like), and active site mutants of proteolytic tryptase, are produced. To produce the various active proteolytic tryptases, a DNA expression construction is used to shuttle DNA between bacteria and yeast. For example, site-directed mutagenesis of tryptase-encoding DNA can be done in conventional *E. coli* hosts, and the mutated DNA then transferred to a suitable eukaryotic host for expression of the novel tryptase.

A preferred embodiment of the invention is directed to a DNA expression construct comprising, in 5' to 3' order: a promoter, the promoter operationally linked to a secretion signal sequence, the secretion signal sequence operationally-linked to a DNA sequence encoding a proteolytic tryptase having an active site mutation, and wherein the expression construct drives expression of a mature proteolytic tryptase that lacks enzymatic activity in hosts transformed to contain the expression construct, the lack of enzymatic activity being due to the active site mutation.

Another preferred embodiment of the invention is directed to a DNA expression construct comprising, in 5' to 3' order: a promoter selected from the group consisting of *AOX1*, *GAP*, *MOX*, *FMD*, *ADH*, *LAC4*, *XPR2*, *LEU2*, *GAM1*, *PGK1*, *GAL7*, *GADPH*, *CYC1*, and *CUP1*, the promoter

operationally linked to a secretion signal sequence, the secretion signal sequence operationally-linked to a DNA sequence encoding proteolytic trypsin having an active site mutation, the DNA sequence operationally linked to a terminator sequence.

5           According to the present invention, DNA encoding proteolytic trypsin is mutated in one of three active site amino acids (amino acids 44, 91, and 194) of proteolytic trypsin. The mutated DNA is cloned into a eukaryotic expression construct, and transformed into a suitable eukaryotic host cell, preferably a yeast host cell. Successfully transformed host cells  
10           express, post-translationally process, and secrete the active site-mutated form of mature trypsin, preferably upon induction of expression.

          Another embodiment of the invention is directed to a recombinant protein lacking trypsin enzymatic activity which is produced by organisms transformed to contain and express the expression construct. Preferably, the  
15           DNA expression construct has a mutation at one of three putative active sites within the proteolytic trypsin gene: histidine at amino acid 44, aspartic acid at amino acid 91, and serine at amino acid 194. The mutation preferably changes the amino acid at these positions to alanine.

          The invention is further drawn to a method of generating polyclonal or monoclonal anti-human proteolytic trypsin antibodies. A preferred  
20           embodiment comprises inoculating an animal with the active site mutants of the proteolytic trypsin produced by organisms transformed to contain and express the expression construct. Other recombinant methods of producing antibodies can also be used including, but not limited to, phage display technology, library screening, and a combination of these two methods.  
25           The invention is also drawn to polyclonal, monoclonal, or chimeric anti-human proteolytic trypsin antibodies produced thereby.

          Another embodiment of the invention is directed to a DNA expression construct comprising, in 5' to 3' order: a promoter, the promoter

operationally linked to a secretion signal sequence, the secretion signal sequence operationally-linked to a DNA sequence encoding proteolytic trypsin, wherein the expression construct drives the expression of mature proteolytic trypsin that has enzymatic activity in hosts transformed to contain the expression construct.

Yet another embodiment of the invention is drawn to a DNA expression construct comprising, in 5' to 3' order: a promoter, the promoter operationally linked to a secretion signal sequence, the secretion signal sequence operationally-linked to a DNA sequence encoding human trypsin  $\beta$ -II having a nucleotide sequence encoding the polypeptide of SEQ ID NO. 6, and wherein the expression construct drives the expression of mature  $\beta$ -II trypsin that has enzymatic activity in hosts transformed to contain the expression construct. The mutation of  $\beta$ -I trypsin at amino acid 102 generates the  $\beta$ -II trypsin sequence identically. There are no other changes throughout the rest of the coding region of  $\beta$ -II trypsin. Although the mutation is generated as a mutation of  $\beta$ -I trypsin, it is referred to hereinafter as  $\beta$ -II trypsin and is identical to the coding region of  $\beta$ -II trypsin. The recombinant  $\beta$ -II trypsin is expressed off the DNA construct which is integrated into the yeast genome. In a preferred embodiment, the genetically engineered yeast cell comprises a *Pichia pastoris* host cell transformed to contain and express the  $\beta$ -II trypsin expression construct as described herein.

The invention entails operationally linking DNA sequences that encode the mature form of proteolytic trypsin immediately downstream (i.e., in the 3' direction) and in-frame to a secretion signal sequence to yield an expression construct. The expression construct, a preferred embodiment of which is a plasmid designated pPIC9-HumTryN102K, then is transformed into a suitable host, preferably a strain of yeast and most preferably a strain of the genus *Pichia*. Hosts so transformed express and secrete the  $\beta$ -II

tryptase encoded by the expression construct. The  $\beta$ -II tryptase expressed is correctly processed by the host cell and secreted into the cell medium as an alternate isoform of tryptase.

5 The invention takes advantage of the fact that native tryptase is synthesized as a proprotein. The modified tryptase amplicon described herein lacks the sequences that encode the N-terminal amino acid prosequence. By cloning this sequence as an in-frame fusion to an N-terminal yeast secretion signal sequence, there is no need to subject the secreted tryptase protein to an activation process. It is secreted as a mature monomer that is cleaved and self-assembling and that spontaneously forms an active tetrameric enzyme without any further exogenous manipulation required.

10 To accomplish this result, the signal peptide cleavage site is positioned immediately adjacent to the N-terminus of mature tryptase protein. Cleavage of the signal peptide by action of a eukaryotic host cell protease then removes the signal peptide from the tryptase as it is secreted. The result is secretion of an enzymatically-active, mature form of tryptase containing the same amino terminal residues found in mature native tryptase molecules isolated from human tissues.

15 A distinct advantage of the method of producing proteolytic tryptase described herein is that the tryptase so produced, unlike previous methods, does not require any exogenous or human-aided post-expression or post-purification modifications or manipulations to initiate tryptase activity. In the invention, the monomer is cleaved as it is secreted. The self-assembly of the monomers into the active tetramer occurs after secretion from the cell. This occurs automatically after secretion. The proteolytic tryptase produced according to the invention has enzymatic activity which compares favorably with cadaveric tryptase.

Other distinct advantages of the method of producing proteolytic tryptase described herein is that the tryptase so produced has high levels of expression. Unlike conventional purification processes in which the enzyme is purified from cadavers, the method described herein and the resultant tryptase lacks the impurities that are commonly found in cadaveric tryptase. There is also a lack of the biohazards associated with using materials of cadaveric sources. The method described herein and resultant tryptase also has a higher uniformity of the purified tryptase and lower batch-to-batch variation. The resultant tryptase also has greater specific activity.

The ready availability of enzymatically-active proteolytic tryptase afforded by the invention immediately provides previously unattained advantages on several fronts. These include facilitating the large scale screening of combinatorial libraries for specific tryptase inhibitors as potential therapeutics, as well as advancing the understanding of the biological significance of tryptase in mast cell-mediated diseases.

The active site mutations of proteolytic tryptase provided by the invention furnish a tool with which to further understanding of the structural and functional properties of this unique protease. Active site refers to a site that is required for enzymatic activity. It is not limited to the surface loop of the active site. The active site mutants described herein are able to form tetramers.

The method according to the invention can be used to produce large standardized lots (> 100 mg or > 5 liters of yeast culture) of tryptase having defined specifications. The method can also easily be scaled to produce tryptase from microgram to gram or kilogram quantities. Using conventional methods to purify tryptase from cadavers, one human lung would result in only about 10 milligrams tryptase.

The quantity of tryptase produced in the preferred *Pichia* transformant is sufficiently large to enable larger-scale tryptase studies than

were possible in the past, such as pharmacological studies, combinatorial library screens, and X-ray crystallographic studies. The large quantity of trypsin produced also allows for the development of trypsin agonists and/or antagonists.

5            These and other aims, objects, and advantages of the invention will become apparent upon a complete reading of the following Detailed Description of the Invention and attached claims.

### BRIEF DESCRIPTION OF THE DRAWINGS

10            **Fig. 1** is an amino acid alignment of proteolytic and non-proteolytic trypsinases. The --▼-- designates the first amino acid in each mature trypsinase. The notations A, B, C, D, 3, 1, and 2 denote the seven loops predicted to form the substrate-binding cleft of each trypsinase based on the structure of bovine pancreatic trypsin and human  $\beta$ -II trypsinase.

15            **Fig. 2** is a schematic diagram of pPIC9.

20            **Fig. 3** is a Western blot of human  $\beta$ -I trypsinase (rh  $\beta$  I),  $\beta$ -II trypsinase (rh  $\beta$  II), and  $\beta$ -trypsinase isolated from a cadaver (native  $\beta$ ). The gel was visualized by probing with biotinylated anti-human trypsinase AA5 monoclonal antibody (Promega Corporation). Glycosidase digestions with PGNase F were performed on the samples. The first three lanes contain the undigested trypsinases. The second three lanes contain the digested trypsinases. The glycosidase digestion yields a single trypsinase core protein.

25            **Fig. 4** is a COOMASSIE-brand dye stained SDS-PAGE of recombinant human  $\beta$ -I and  $\beta$ -II trypsinases and native trypsinases showing the glycosylation status of the proteins.

**Fig. 5** is a Western blot of *Pichia pastoris* fermentation induction of human  $\beta$ -I trypsinase and two of its active site mutants (H44A and S194A). The gel was visualized by probing with biotinylated anti-human trypsinase AA5 monoclonal antibody (Promega Corporation). A CBZ-Lys-S-

Thiobenzyl Ester/DNTB Coupled Cleave Assay was performed on the loaded samples. The corresponding units/ml/min from the Assay are shown at the bottom of the gel.

5 **Fig. 6** is a Western blot of *Pichia pastoris* induction supernatant at 64 hours from eight different human  $\beta$ -II S194A active site mutant clones. A CBZ-Lys-S-Thiobenzyl Ester/DNTB coupled cleavage assay was performed on the loaded samples. The corresponding units/ml/min from the assay are shown at the bottom of the gel.

10 **Fig. 7** shows molecular weight determinations for human  $\beta$ -I and  $\beta$ -II tryptase and a  $\beta$ -I tryptase mutant, S194A, by gel filtration.

**Fig. 8** is a graph illustrating the inhibition of human  $\beta$ -I and  $\beta$ -II tryptase by the irreversible serine protease inhibitor AEBSF.

15 **Fig. 9** shows a bioassay comparison of the cleavage and inactivation of fibrinogen by human  $\beta$ -tryptases.

## DETAILED DESCRIPTION OF THE INVENTION

### **Definitions:**

20 To provide a clear and consistent understanding of the specification and claims, the following definitions are used herein. Terms not expressly described have their standard meaning as understood by those skilled in the art.

25 **Active site mutant** - Active site refers to a site that is required for enzymatic activity. It is not limited to the surface loop of the active site. As used herein, the active sites of proteolytic tryptase are amino acids 44, 91, and 194 or their comparable amino acids in the proteolytic tryptases. The active site mutants of proteolytic tryptase described herein are able to be cleaved and to form tetramers. The active site mutants lack enzymatic activity. This lack of activity is not due to the inability to form a mature tetramer, but instead is due to the mutation in the active site.

**Enzymatically-active proteolytic tryptase** - As applied to the expression of heterologous proteins from a genetically-engineered host cell, a protein is enzymatically active when it does not require post-expression or post-isolation chemical processing such as artificial cleavage of a secretion signal peptide or artificial glycosylation in order for the expressed/isolated protein to have the desired activity. Proteolytic tryptase must be correctly formed into the tetrameric form to be enzymatically active. Used synonymously with "mature proteolytic tryptase."

**Expression construct** - A DNA construct containing at least one sub-sequence encoding a protein or peptide of interest which is operationally linked to one or more regulatory sub-sequences which drive expression of the encoded protein or peptide when the construct is transformed into a suitable host cell. Such constructs also may contain sub-sequences encoding means for selecting host cells transformed to contain the construct, such as sub-sequences which confer antibiotic resistance or dietary limitations to transformed cells.

**Host cells** - In general, any eukaryotic cell amenable to transformation, including, but not limited to, organisms of the genera *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, *Schwanniomyces*, *Yarrowia*, and the like, including *Hansenula polymorpha*, *Kluyveromyces lactis*, *Pichia pastoris*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Schwanniomyces occidentalis* and *Yarrowia lipolytica*. It is preferred that the host be of the genus *Pichia* and most preferred that the host cell be a *Pichia pastoris* having the characteristics of ATCC 20864.

**Mature, Proteolytic Tryptase** - As applied to the expression of heterologous proteins from a genetically-engineered host cell, a protein is enzymatically active when it does not require post-expression or post-isolation chemical processing such as artificial cleavage of a secretion signal

peptide or artificial glycosylation in order for the expressed/isolated protein to have the desired activity. Proteolytic trypsin must be correctly formed into the tetrameric form to be enzymatically active. Used synonymously with "enzymatically-active proteolytic trypsin."

5           **Non-proteolytic trypsin** - A form of trypsin that is not cleavable and does not self-assemble. Examples of non-proteolytic trypsin include, but are not limited to,  $\alpha$ -trypsin. It should be noted that trypsin nomenclature in the prior art has not been consistent.

10           **Operationally linked** - When referring to joined DNA sequences, denotes that the sequences are in the same reading frame and that upstream regulatory sequences will perform as such in relation to downstream structural sequences. DNA sequences which are operationally linked are not necessarily physically linked directly to one another but may be separated by intervening nucleotides which do not interfere with the operational relationship of the linked sequences.

15           ***Pichia pastoris*** - Any strain of the species *Pichia pastoris*, including, but not limited to, those strains having the characteristics of the deposited strains bearing American Type Culture Collection (ATCC, 10801 University Blvd., Manassas, Virginia, 20110-2209, U.S.A.) Accession Numbers 2604, 20864 (synonymous with strain GS115), 28485, 60372, 66390-66395, 76273, and 76274, as well as *Pichia pastoris* strain KM71, available commercially from Invitrogen Corporation (San Diego, California, U.S.A.). ATCC 20864 (strain GS115) and strain KM71 are the preferred host cell types.

20           **Polymerase Chain Reaction (PCR)** - A technique in which cycles of denaturation, annealing with a primer pair, and extension with DNA polymerase are used to generate a large number of copies of a desired polynucleotide sequence. See U.S. Patent Nos. 4,683,195 and 4,683,202 for a description of the reaction.

**Promoter** - A DNA sequence at which RNA polymerase binds and which directs the specific transcription of downstream (i.e., 3') DNA sequences into corresponding RNA sequences. A promoter functions as the start signal for RNA synthesis. The promoter itself is not transcribed.

5           **Proteolytic tryptase** - A tryptase that is cleavable in its protryptase form and that is self-assembling, wherein monomers are assembled into tetramers without any exogenous or human-aided post-expression or post-purification modifications or manipulations to initiate tryptase activity. Examples of proteolytic tryptases include, but are not limited to,  $\beta$ -I tryptase (formerly referred to as skin tryptase)  $\beta$ -II tryptase (formerly referred to as lung tryptase),  $\beta$ -like tryptases, and transmembrane tryptase. It should be noted that tryptase nomenclature in the prior art has not been consistent.

10           **Secretion signal peptide** - An N-terminal extension of generally from 10 to 85 predominately hydrophobic amino acid residues. The secretion signal peptide is encoded by the secretion signal sequence and initiates a secretory pathway resulting in mobilization of the mature protein out of the cytoplasmic compartment. The secretion signal peptide is cleaved from the mature protein chain post-translation and forms no part of the mature protein. The expressed protein must be secreted in order to form the enzymatically-active tetrameric form of proteolytic-tryptase.

15           **Secretion signal sequence** - A DNA sequence located between the transcription start site of an operon and the first structural gene. The secretion signal encodes a short peptide called the secretion signal peptide.

20           **Self-assembling tetrameric tryptase** - A tryptase that is cleavable and that self-assembles. Included in this term are proteolytic tryptases. While the inventors do not wish to be limited to a particular mode of self-assembly, it is believed R-V at amino acids -3 and -2 from amino acid 1 (the

first amino acid of the cleaved proteolytic tryptase) are essential to this activity.

**Terminator** - A DNA sequence situated at the 3' end of a transcribed sequence that signals the end of transcription.

5           **Tryptase:** Unless expressly identified otherwise, proteolytic tryptase.  
**Genetic Engineering:**

10           Many of the steps noted below for the manipulation of DNA, including digesting with restriction endonucleases, amplifying by PCR, hybridizing, ligating, separating and isolating by gel electrophoresis, transforming cells with heterologous DNA, selecting successful transformants, and the like, are well known and widely practiced by those skilled in the art and are not extensively elaborated upon herein. Unless otherwise noted, the DNA protocols utilized herein are described in *Sambrook, Fritsch, and Maniatis* (1989).

15           **RECOMBINANT, ENZYMATICALLY-ACTIVE PROTEOLYTIC TRYPTASE**

20           Proteolytic tryptases are cleavable and self-assembling tryptases that form into enzymatically-active tetramers. Non-proteolytic tryptases are not cleavable. Cleavage is required for spontaneous assembly. Thus, non-proteolytic tryptases do not self-assemble. As is shown in the amino acid alignment of **Fig. 1**, the proteolytic tryptases of humans share certain sequence similarities. In particular, the amino acids RV are found at amino acids at positions -3 and -2 from amino acid 1, which is the first amino acid of the cleaved proteolytic tryptase. The RV motif has been implicated in the cleavage of proteolytic tryptase. The RV motif is absent in  $\alpha$ -tryptase, which is not cleavable, and thus does not self-assemble into tetramers.

25           Unlike previous recombinant tryptases, the proteolytic tryptases of the invention include the sequences before the cleavage site, the presence of

5 which permit the proteolytic tryptases to be cleaved and self-assemble. Included in proteolytic tryptases are  $\beta$ -II and  $\beta$ -II tryptases,  $\beta$ -like tryptases, and transmembrane tryptases. Human  $\beta$ -I and  $\beta$ -II differ by one amino acid at position 102 ( $\beta$ -I has asparagine, whereas  $\beta$ -II has lysine). Furthermore, human  $\beta$ -I is glycosylated at two N-linked sites, whereas  $\beta$ -II at only one site. While this difference has been predicted by sequence analysis, the recombinant proteins provided by the invention are the first to demonstrate the N102 is actually glycosylated. Amino acid N204, which is present in  $\beta$ -tryptase and  $\alpha$ -tryptase, is thought to be glycosylated in all  $\beta$ -tryptases and  $\alpha$ -tryptases.

## RECOMBINANT, ENZYMATICALLY-ACTIVE $\beta$ -I TRYPTASE

### Isolation of $\beta$ -I Tryptase-Encoding DNA:

15 Referring to the construct of Example 1a, the DNA sequence encoding  $\beta$ -I tryptase was isolated by first collecting mast cell samples ( $4 \times 10^6$ , 1.1% of total cells) from a donor. Poly(A)<sup>+</sup> RNA was then isolated by LiCl precipitation and oligo(dT)-cellulose chromatography. A cDNA library was constructed in a suitable phage vector ( $\lambda$  ZAP II vector, Stratagene, LaJolla, California, U.S.A.) and amplified once in *E. coli* XL1-Blue cells prior to screening.

20 The library of Example 1a was screened at 42°C with a dog tryptase cDNA <sup>32</sup>P-labeled to  $2 \times 10^8$  cpm/ $\mu$ g by nick-translation, in conventional fashion except for using 30% formamide in the hybridization solution and 5 x SSC. Positive recombinants were identified by autoradiography, plaque-purified, and re-probed. Phagemids containing inserts that hybridize to the cDNA probe were excised from the phage vector using R408 helper phage, transformed into *E. coli* XL1-Blue cells, and purified by alkaline lysis. The sequence of the cDNA inserts was determined by dideoxy chain termination modified for double-stranded DNA by using SEQUENASE-

brand sequencing kit (United States Biochemical, Cleveland, Ohio, U.S.A.). The M13 forward, reverse, and KS primers (Stratagene) were used for the initial sequence reaction. Subsequent sequencing reactions used oligonucleotide primers designed from the previously determined sequence.

5 Positive clones were also used to screen commercial libraries, such as the human placental genomic library in EMBL-3 (Clontech, Palo Alto, California, U.S.A.). Here, the cDNA was labeled with biotin-7-dATP by nick-translation and hybridized at 50°C to the immobilized phage DNA and visualized. Positive clones were plaque-purified and re-screened. Phage  
10 DNA was purified by the plate lysate method in conventional fashion and digested with *Bam* HI to yield genomic fragments. The genomic fragments were separated by agarose gel electrophoresis, transferred to nitrocellulose, and hybridized to tryptase cDNA. Hybridizing fragments were ligated into the *Bam* HI site of pBluescript KS(+) phagemid (Stratagene), and the nucleotide sequence determined as described for the cDNAs. See  
15 *Vanderslice et al.* (1990).

A DNA sequence of a  $\beta$ -I tryptase encoding fragment isolated as described above is depicted in SEQ. ID. NO. 5, which encodes the amino acid shown in SEQ. ID. NO. 6. The amino acid of SEQ. ID. NO. 6 is  
20 cleaved to form the mature proteolytic tryptase, which is described as SEQ. ID. NO. 2. The DNA sequence of the mature  $\beta$ -I tryptase encoding fragment is depicted as SEQ. ID. NO. 1 (the encoded protein is shown in SEQ. ID. NO. 2).

#### 25 **Incorporation of $\beta$ -I Tryptase DNA Into Expression Construct:**

Referring to Example 1a, the DNA encoding the  $\beta$ -I tryptase was then operationally linked with suitable regulatory sub-sequences to drive expression of the tryptase-coding sequence in a eukaryotic host, to yield an expression construct. Preferably, the construct also contains one or more

sub-sequences to enable the easy identification of positive transformants. At a minimum, the expression construct should include, operationally linked in 5' to 3' order, a promoter sequence, a secretion signal sequence, the  $\beta$ -I tryptase coding sequence, and a terminator sequence. In this fashion, the promoter will initiate transcription of the downstream secretion signal sequence and  $\beta$ -I tryptase structural gene when incorporated into a suitable host.

Several plasmids containing the required regulatory sub-sequences, as well as sub-sequences encoding selectable antibiotic and/or auxotrophic markers and multiple cloning sites are available commercially. A preferred plasmid, pPIC9, is available from Invitrogen (San Diego, California, U.S.A.). A schematic of pPIC9 is provided in Fig. 2.

pPIC9 is a circular DNA plasmid of 8023 base pairs and contains a 5' *AOX1* promoter fragment at bases 1-948, an  $\alpha$ -Factor secretion signal (designated S in Fig. 2) at bases 949-1218, a multiple cloning site at bases 1192-1241, and a 3' *AOX1* terminator fragment (designated 3' *AOX1* (TT)) at bases 1253-1586. pPIC9 also contains an ampicillin resistance gene at bases 7713-6853 and a *ColE1* origin at bases 6708-6034. The multiple cloning site includes recognition sites for *Xho* I, *Sna* BI, *Eco* RI, *Avr* II, and *Not* I. The plasmid also contains *Bgl* II, *Sac* I, *Sal* I, and *Stu* I recognition sites.

Other eukaryotic promoter and terminator sequences can be used with comparable success in the expression construct. Generally, the promoter should be homologous to the chosen host in order to ensure efficient expression of the encoded tryptase, although this is not required. The promoter may be constitutive or inducible. Suitable eukaryotic promoter and terminator sequences include (in addition to *AOX1*) *GAP*, *MOX*, *FMD*, *ADH*, *LAC4*, *XPR2*, *LEU2*, *GAM1*, *PGK1*, *GAL7*, *GADPH*, *CYC1*, *CUP1*, and the like. This list is illustrative, not exclusive.

As shown in Example 1a, the DNA sequence encoding the  $\beta$ -I tryptase was introduced into the multiple cloning site of pPIC9 by modifying the 5' and 3' ends of the isolated tryptase DNA sequence to yield complementary overhangs with the sticky ends afforded by the restriction sites contained in the multiple cloning site of pPIC9. The pPIC9 plasmid and the amplified  $\beta$ -I tryptase fragments were then digested with suitable restriction enzymes, hybridized, ligated (T4 DNA ligase), transformed (calcium chloride) into a suitable bacterial host (*E. coli* strain JM109, Promega Corporation, Madison, Wisconsin, U.S.A. is preferred), and positive clones selected by ampicillin resistance, all in conventional and well-known fashion.

To modify the ends of the  $\beta$ -I tryptase encoding DNA fragment, the  $\beta$ -I tryptase DNA was amplified using partially homologous nucleotide primers which include suitable restriction nuclease recognition sites but which do not alter the amino acid sequence of the encoded protein. The resulting amplicon thus encodes the same protein, but includes the restriction sites needed to incorporate the  $\beta$ -I tryptase encoding fragment into an expression construct. Using knowledge of the  $\beta$ -I tryptase DNA sequence and the degeneracy of the DNA code, any number of suitable primers which will introduce an appropriate recognition site without altering the amino acid sequence of the encoded peptide can be constructed.

As described more fully in the Examples, amplifying the DNA sequence as shown in SEQ. ID. NO. 5 with the illustrative primers depicted in SEQ. ID. NO. 3 and SEQ. ID. NO. 4 yielded an amplified  $\beta$ -I tryptase encoding DNA fragment which includes an *Xho* I restriction site near the 5' end of the fragment and a *Not* I restriction site near the 3' end of the fragment. These two restriction sites are exemplary only. Virtually any restriction site can be introduced at the terminal ends of the  $\beta$ -I tryptase encoding DNA fragment without altering the sequence of the encoded  $\beta$ -I

tryptase enzyme. The choice is up to the user, and depends almost entirely upon the nature, location, and number of the restriction sites available in the other sub-sequences which are to be incorporated into the ultimate expression construct.

5           The modified amplicon containing the terminal *Xho* I and *Not* I sites can then easily be inserted into any plasmid or construct containing an *Xho* I recognition site and a *Not* I recognition site, in conventional and well-known fashion.

10           Other sub-sequences may also be included in the expression construct. One particularly helpful sub-sequence is a secretion signal sequence encoding a signal peptide to direct the secretion of the expressed protein from the cell. The signal peptide forms no part of the mature protein - the signal peptide is cleaved from the protein as it passes through the cell wall, thereby yielding the mature protein. For purposes of the present invention, the preferred secretion signal sequence is one that encodes a KEX2 cleavage site in the unprocessed protein. The action of KEX2, a yeast signal peptidase, then will cleave the signal peptide from the remainder of the protein, thereby yielding the mature  $\beta$ -I tryptase enzyme. An  $\alpha$ -Factor secretion signal sub-sequence is preferred for secretion of the recombinant  $\beta$ -I tryptase using a *Pichia* host.

15           As is detailed in Example 1a, after transforming the  $\beta$ -I tryptase encoding construct into a bacterial host for cloning, positive transformants were screened for the properly assembled expression construct by restriction analysis of plasmids isolated from ampicillin-resistant colonies. The expression constructs were then isolated in standard fashion and transformed into a suitable eukaryotic host for expression of the human  $\beta$ -I tryptase encoded thereon.

#### **Transformation of Eukaryotic Host:**

The expression construct encoding human  $\beta$ -I tryptase then was incorporated into a suitable eukaryotic host as described in Example 2a. The preferred host is a yeast cell. A eukaryotic host must be used so that the expressed  $\beta$ -I tryptase is properly processed by the cell after translation. Post-translational intracellular processing by the eukaryotic host is critical to impart enzymatic activity to the mature protein.

The preferred hosts include *Hansenula polymorpha*, *Kluyveromyces lactis*, *Pichia pastoris*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Schwanniomyces occidentalis* and *Yarrowia lipolytica*. It is most preferred that the host be of the genus *Pichia*. From among *Pichia*, it is most preferred that the host cell be a *Pichia pastoris* cell having the characteristics of ATCC 20864 (strain GS115) or KM71 (Invitrogen).

Transformation is preferably accomplished by electroporation in conventional fashion. The host cells were made electrocompetent by extensive washing with 1 M Sorbitol and then mixed with aliquots of the expression construct which have been pre-digested with a suitable single-cutting restriction enzyme (e.g., in pPIC9, *Sal* I or *Sac* I) and transformed. Successfully transformed auxotrophs were screened on minimal media, and then rescreened on fresh media to identify clones which produce high levels of tryptase.

If operationally linked to an inducible promoter, successfully transformed auxotrophs are screened in a medium containing the required inducer to initiate  $\beta$ -I tryptase production.

$\beta$ -I tryptase can be assayed from the culture broth using an enzyme-linked immunosorbent assay as described in *Niles and Haak-Frendscho*, U.S. Patent 5,594,116, issued January 14, 1997 and assigned to Promega Corporation, and which is incorporated herein by reference. Briefly, suitable microtiter plates were coated with capture antibodies specific for human tryptase derived from immunized avians, preferably chickens. This

was done by coating the microtiter plates with a solution of the capture antibody and incubating for 8 to 48 hours at 4°C. The coated plates were then thoroughly rinsed with a solution of TBST (tris-buffered saline with Tween 20. Non-specific residual binding to the microtiter plate itself was then blocked by coating the plate with a blocking buffer. A commonly used blocking buffer is a solution of 0.05% Tween 20 containing bovine serum albumin (BSA). The plates were again rinsed with TBST.

The solutions to be tested were then diluted in the blocking buffer. Preparing a number of serial dilutions is recommended. The plates were then coated with the test solutions and incubated for at least two hours at room temperature.

After incubation the plates were again rinsed with TBST. Other buffered solutions, such as phosphate-buffered saline or phosphate-buffered saline with Tween, also may be used.

The next step is to introduce a tryptase detect antibody solution which binds to the captured tryptase. The preferred detect antibody is a murine-derived monoclonal antibody specific to tryptase. A solution of the monoclonal antibody was prepared and the wells are coated and incubated for at least two hours at room temperature. After incubation, the plates were again washed with TBST.

The plates were rinsed with TBST, and were then coated with a specific antibody/horseradish peroxidase conjugate. Such antibody/horseradish peroxidase conjugates are well known in the art. A conventional method to prepare such conjugates includes using sodium periodate to oxidize the carbohydrate side chains of horseradish peroxidase, followed by the formation of a Schiff base between the activated peroxidase and amino groups of the antibody. The preferred antibody for the conjugate is goat anti-mouse IgG antibodies. The Schiff base then was reduced (sodium borohydride) to yield a stable antibody/enzyme conjugate. The

wells of the microtiter plates then were incubated for at least two hours at room temperature. It is important here that the conjugate antibodies must not react with the capture antibody or the trypsin itself. It is preferred that the plates be rinsed with TBS three times prior to addition of the substrate.

5           A horseradish peroxidase substrate solution was then added to each well and the wells incubated for 15 min at room temperature. Acid was added to stop the color reaction. The wells then were examined spectrophotometrically at 450 nm. For colorimetric detection, horseradish peroxidase-conjugated anti-mouse antibody used in conjunction with the substrate 3,3',5,5'-tetramethylbenzidine (TMB) is preferred. Other peroxidase substrates, such as *o*-phenylenediamine dihydrochloride (OPD) and anti-mouse alkaline phosphatase conjugates function with equal success. This colorimetric double antibody-sandwich ELISA has a sensitivity of about 20 pg/ml, a linear response range from 15 to 2000 pg/ml, and an  $r \geq 0.99$ .

10           The CBZ Lys-Thiobenzyl Ester/DNTB Coupled Cleavage Assay or other enzyme cleavage assays can also be used to assay for enzymatic activity of  $\beta$ -I trypsin.

## 20           **RECOMBINANT, ENZYMATICALLY-ACTIVE $\beta$ -II TRYPTASE**

### **Convert Human $\beta$ -I Trypsin into Recombinant Human $\beta$ -II Trypsin:**

25           Human  $\beta$ -I and  $\beta$ -II trypsin have identical amino acid sequences except for amino acid 102:  $\beta$ -I trypsin has an asparagine residue, whereas  $\beta$ -II trypsin has a lysine residue. As is explained in more detail in Example 1b, amino acid 102 was mutated in the  $\beta$ -I trypsin clone pPIC9-HumTry, converting asparagine to lysine, thereby changing the amino acid sequence from that of  $\beta$ -I trypsin to that of  $\beta$ -II trypsin. The new clone was designated clone pPIC9-HumTryN102K. The gene was mutated with the

GeneEditor *in vitro* Site Directed Mutagenesis Kit™ (Promega Corporation), following the kit directions. The oligonucleotide used for this mutation was SEQ. ID. NO. 7:

(5'-GAGGAGCCGGTGAAGGTCTCCAGCCAC-3'). The resultant mutated tryptase DNA, i.e., the recombinant  $\beta$ -II tryptase, is shown in SEQ. ID. NO. 8, and its amino acid sequence is described in SEQ. ID. NO. 9. The peptide of SEQ. ID. NO. 9 is cleaved to form the mature  $\beta$ -II tryptase, which has the amino acid depicted in SEQ. ID. NO. 11. The DNA that encodes the cleaved, mature  $\beta$ -II tryptase is shown in SEQ. ID. NO. 10.

As detailed in Example 1b, the mutation reactions were used to transform bacterial strain BMH71-18 (contained in the kit). Other strains that contain a transposon insertion in the *mutS* gene, such as ES1301, can be used with equal success. BMH71-18 *mutS* competent cells are preferred. DNA was isolated from the cells and was used to transform JM109 *E. coli* cells. DNA isolated from the JM109 cells was digested with restriction enzymes to confirm the mutagenesis of amino acid 102.

#### **Transform Pichia with the pPIC9-HumTryN102K DNA:**

The expression construct pPIC9-HumTryN102K encoding the human  $\beta$ -II tryptase then was incorporated into a suitable eukaryotic host, as described above. A eukaryotic host must be used so that the expressed  $\beta$ -II tryptase is properly processed by the cell after translation. Post-translational intracellular processing by the eukaryotic host is critical to impart enzymatic activity to the mature protein. As noted above, the expression constructs can be incorporated into any suitable eukaryotic host, yeast being preferred. The preferred hosts include *Hansenula polymorpha*, *Kluyveromyces lactis*, *Pichia pastoris*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Schwanniomyces occidentalis* and *Yarrowia*

*lipolytica*. It is most preferred that the host be of the genus *Pichia*. From among *Pichia*, it is most preferred that the host cell be a *Pichia pastoris* cell having the characteristics of ATCC 20864 (strain GS115), SMD1168 (Invitrogen), or KM71 (Invitrogen). Example 2b details the transformation of *Pichia pastoris* strains SMD1168, GS115, and KM71 with the pPIC-HumTry N102K construct. The pPIC9-HumTryN102K DNA was digested with *Sal* I prior to transformation into the host.

Host cells are transformed by electroporation in a conventional fashion and screened as described above. If operationally linked to an inducible promoter, successfully transformed auxotrophs are screened in a medium containing the required inducer to initiate tryptase production as described above.

#### **Best Expression Response:**

Clones can be validated for the best expression response. For this, single colonies of various clones were transferred to 50 ml YPD broth cultures (contents/L: 20g Peptone-Y, 10g yeast extract-Y, 20g dextrose, pH6.5 at 30°C). Cells were grown overnight at 30°C with shaking. The following day, the  $A_{600}$  of the overnight cultures was checked. For each clone, cells (300  $A_{600}$  units) were centrifuged in a clinical centrifuge for 10 minutes at 2500 rpm. The cells were resuspended in 25 ml BMMY (buffered minimal methanol complex media; which is BMGY containing 0.5% methanol, but without 1% glycerol). BMGY is buffered minimal glycerol complex media, which contains 100 mM potassium phosphate, pH 6.0, 10 g/L yeast extract, 20 g/L peptone, 13.4 g/L yeast nitrogen base, 0.4 mg/L biotin, and 1% glycerol. Both BMMY and BMGY are commercially available from Invitrogen. The cells were transferred to 500 ml BMMY cultures. The  $A_{600}$  of the inoculated cultures were then checked. The cells were grown overnight at 30°C with shaking.

The following day, a 5 ml sample of each culture was removed, and the  $A_{600}$  of each culture was checked. Each culture was fed 2.5 ml of methanol. The media was supplemented with 5 ml of 50 mg/ml heparin (prepared in BMMY). Cells were grown overnight at 30°C with shaking. The following day, a 5 ml sample from each culture was removed. The  $A_{600}$  of each culture was checked. Each culture was then fed another 2.5 ml of methanol. Cells were grown overnight at 30°C with shaking. The following day, a 5 ml sample from each culture was removed, and the  $A_{600}$  of each culture was checked. From an analysis of the  $A_{600}$ , the growth curves can be compared to each other. The activity data can also be compared.

#### **End Uses for Enzymatically-Active Recombinant Proteolytic Tryptase:**

A distinct advantage of the recombinant proteolytic tryptase described herein is that it is enzymatically active. Because the recombinant proteolytic tryptase is active, it can be used in any application which would otherwise require using a cadaveric tryptase.

For instance, because the recombinant proteolytic tryptase of the invention has the same biological activity as cadaveric tryptase, it can be used as an antigen to generate anti-human tryptase antibodies in various animals. This is done in well-known and conventional fashion by inoculating a test animal, such as a mouse, rat, rabbit, guinea pig, chicken, goat, or other animal, with an initial inoculation of the recombinant tryptase, followed by a series of booster injections. The injections initiate an immunogenic reaction in the animal, resulting in the production of polyclonal antibodies to the recombinant tryptase.

To isolate the antibodies, the IgG fraction of the blood serum (or from egg yolks in the case of avians) is isolated in standard fashion. With egg yolks, this can be accomplished utilizing a commercial product such as

Promega Corporation's "EGGstract"™ IgY Purification System (Promega Corporation, Madison, Wis. U.S.A.). There also are a number of other methods for isolating immunoglobulins from serum or egg yolks, such as other sequential precipitation methods, which are well known to those skilled in the field. See, for instance, *Scopes, R. K.* The conventional method of protein isolation, which is completely satisfactory to isolate anti-human trypsin antibodies, is to "salt out" the protein fractions by precipitation of the proteins from a salt solution. The IgY polyclonal antibodies from the serum of the test animal can be isolated using, for instance, chromatographical methods. Again, there are a number of methods well known to those skilled in the art for isolating immunoglobulins from serum or egg yolk samples.

In the same fashion, the recombinant proteolytic trypsin described herein can be used to generate monoclonal anti-human trypsin antibodies using conventional hybridoma technology. In this technology, a mouse or other test animal is immunized with the recombinant human trypsin to initiate the required immunogenic response. For murine-derived monoclonal antibodies, pristane-primed mice are widely utilized. Spleen cells from the immunized animals are then immortalized by fusion with an immortal cell line, such as a myeloma cell line. The hybrid cells are then serially-diluted, cultured, and screened for those cells which secrete antibodies specific for the recombinant trypsin. The monoclonal antibodies so formed can be used in any number of applications, such as assaying to detect human trypsin, epitope mapping of human trypsin, or for inhibiting trypsin activity for therapeutic or other applications. Other recombinant techniques of making antibody such as those described above can be used to make antibodies to the recombinant proteolytic trypsin.

The recombinant proteolytic trypsinases of the present invention can also be used in drug screening for compounds which act as trypsin

inhibitors, antagonists, agonists, etc. For example, to screen for tryptase inhibitors, the recombinant proteolytic tryptase of the present invention can be contacted with a putative tryptase inhibitor. The effectiveness of the inhibitor is then determined by measuring the loss of tryptase enzymatic activity as compared to a standard curve of tryptase activity.

Likewise, the same approach can be used to screen promising drug candidates for their effects on the enzymatic activity of proteolytic tryptase. This can be done with the recombinant proteolytic tryptase in solution phase. Because the subject recombinant proteolytic tryptase is enzymatically active, the effect of any given compound on the proteolytic tryptase can easily be determined by measuring the effect the compound has on the enzymatic activity of the proteolytic tryptase.

Other uses for the recombinant proteolytic tryptase include screening chemical libraries, peptide libraries, and the like. The recombinant proteolytic tryptase can also be used for *in vitro*, *in vivo*, and *ex vivo* testing of substances. Additionally, modeling can be done on the recombinant proteolytic tryptase.

The recombinant proteolytic tryptase can also be used to assay for the presence of proteolytic tryptase in biological or other solutions. For example, the recombinant tryptase can be used to develop enzyme-linked immunosorbent assays (ELISAs) for human tryptase. See, for example, U.S. Patent No. 5,744,319 to *Niles* and *Haak-Frendscho* for a description of a double antibody-sandwich ELISA, which is incorporated herein by reference. ELISAs come in many different, but related formats, all of which are exceedingly well known to those skilled in the field. A format widely used due to its relative ease of use and wide linear response range is known as the double antibody-sandwich ELISA. The basic protocol for a double antibody-sandwich ELISA is as follows: A plate is coated with antibodies (called capture antibodies) specific for the immunoglobulin being

assayed. In this case, the capture antibodies are polyclonal or monoclonal antibodies specific for the recombinant tryptase which are isolated as described above. The plate then is washed with a blocking agent, such as bovine serum albumin (BSA) to block non-specific binding of immunoglobulins to the test plate. The solution to be tested for the presence of tryptase then is incubated on the plate coated with the capture antibodies. The plate then is washed, incubated with detect antibodies, washed again, and incubated with a specific antibody-enzyme conjugate. After incubation, the unbound conjugate is washed from the plate and enzyme substrate is added. The presence of the bound antibody-enzyme conjugate results in a proportional color change which can be measured and quantified.

For detecting very low levels of proteolytic tryptase, levels which might be below the detection limit of a given assay, the recombinant proteolytic tryptase can be used in known quantities (or activities) to spike samples, thereby increasing the concentration of tryptase in the samples being assayed above the detection limit and into the linear response range of the assay being used.

Because the present invention enables the production of large amounts of enzymatically active recombinant proteolytic tryptase which can be extensively characterized and subjected to quality control measures, antibodies against the recombinant tryptase can be raised and utilized in any number of assay formats to detect the presence of tryptase and to measure the effect of different compounds on the enzymatic activity of tryptase.

The recombinant proteolytic tryptases that the invention provide can be used to study homotetramers of proteolytic tryptase. Previously, enzymatically-active proteolytic tryptases were made only *in vivo*, where the products from the various proteolytic tryptase genes (e.g.,  $\beta$ -I and  $\beta$ -II) formed heterotetrameric proteolytic tryptases. That is, a single molecule of tetrameric, enzymatically-active proteolytic tryptase was made of different

monomers. In contrast, in the proteolytic tryptases provided by the invention, a single, tetrameric molecule of enzymatically-active proteolytic tryptase is made with the same monomer (e.g., only  $\beta$ -I monomers make up the tetramer).

5 Furthermore, the enzymatically-active recombinant  $\beta$ -II tryptase can be used as a control in experiments to decipher the differences between  $\beta$ -I and  $\beta$ -II tryptase. This is especially useful in view of the fact that tryptase prepared from cadavers is never 100% pure. Instead, human cadaveric tryptase is a mixture of  $\alpha$ -tryptase and the various forms of  $\beta$ -tryptase. 10 Thus, the enzymatically-active recombinant  $\beta$ -II tryptase can be used as a control in experiments to decipher the differences between  $\alpha$ -tryptase and the various forms of  $\beta$ -tryptase (see Fig. 3).

#### ACTIVE SITE MUTANTS OF $\beta$ -TRYPTASE:

15 *Sub 3* The active sites of tryptase have been predicted to be located at seven loops (A, B, C, D, 3, 1, and 2) as shown in Fig. 1. To confirm this, mutations were made to amino acids 44, 91, and 194. Non-conserved changes were made in various amino acids. Amino acids 44, 91, and 194 were changed to alanine. However, amino acids can be mutated to any non- 20 charged residue. According to molecular modeling, these single point mutations were not expected to disrupt the secondary structure.

As can be seen from Fig. 1, amino acid 44 is located within the putative B loop, amino acid 91 is located in the C terminus direction to loop C, and amino acid 194 is within loop 1. Amino acids 44, 91, and 194 are 25 called the catalytic triad. To determine whether the active sites for proteolytic tryptase include histidine at residue 44, asparagine at residue 91, and serine at residue 194, mutants in the putative active sites were generated with the QuikChange™ Site Directed Mutagenesis Kit (Stratagene, LaJolla, California) (described in detail in Example 1c).

As detailed in Example 1c, the mutation reactions were used to transform bacterial strain Epicurian Coli® XL1-Blue supercompetent cells. The constructs were then transformed into a suitable eukaryote host as described in Example 2c. Pichia cells are preferred. Briefly, the DNA was first linearized. The linearized DNA was added to the Pichia GS115 cells, and electroporated as described above. The transformed Pichia was screened for mut<sup>+</sup> and mut<sup>s</sup> phenotypes.

#### **Specific Cleavage Activity of Active site mutants:**

As is shown in Examples 4a-4b, the specific activity of the unpurified  $\beta$ -I and  $\beta$ -II tryptase having active site mutations was determined by the CBZ-Lys-Thiobenzl Ester cleavage assay. After the proteolytic tryptase was purified as detailed in Example 5, the specific activity was assayed again. As is detailed in Example 6b, the specific activity of the active site mutants of  $\beta$ -I and  $\beta$ -II tryptase was approximately 1000-fold less than the recombinant, enzymatically-active  $\beta$ -I and  $\beta$ -II tryptase proteins.

#### **Verification of Production of Tryptase by Active Site Mutants:**

To verify that the lack of specific activity of the active site mutants of  $\beta$ -I and  $\beta$ -II tryptase was due to the mutations in the active site and not due to a lack of mature, proteolytic tryptase expression, the expression in the active site mutants was verified with Western blots using antibodies to  $\beta$ -tryptase as is detailed in Example 3b. As is shown in Example 7, gel filtration analysis of  $\beta$ -I and  $\beta$ -II tryptase and the S194A  $\beta$ -I tryptase active-site mutant further confirmed that the active site mutant was a tetramer.

#### **End Uses of Active Site Mutants of Proteolytic Tryptase:**

Uses for active site mutants of proteolytic tryptase include the following. Both *in vitro* and *in vivo* activity studies have been conducted on

tryptase. Many broad spectrum protease inhibitors are known to be efficacious *in vitro*, but highly toxic *in vivo*. Unfortunately, there is no known natural inhibitor of tryptase. Therefore, data interpretation is complicated in these *in vivo* studies. It is difficult to fully reconcile the physiological effects of excipient buffer (including NaCl, MES, buffer, glycerol, and heparin), protein load, endogenous contaminating pyrogen or small molecule Pichia allergen. The active site mutants provide an inhibited form of proteolytic tryptase. Thus, *in vivo* studies can be conducted with the active site mutants without the complications listed above. *In vitro*, *ex vivo*, and other studies can also be performed with the active site mutants. Additionally, the active site mutants can be used for modeling studies.

Furthermore, active site mutant of the tryptase enzymes can be used to supplement further these studies. Single amino acid substitutions at amino acids 44, 91, and 194 in both recombinant human  $\beta$ -I and  $\beta$ -II tryptase isoforms reduced the specific activity of the recombinant tryptase to less than 1% of the activity of unmutagenized enzyme. These reduced-activity proteolytic tryptases provide an ideal control for *in vivo* experimentation because they are highly purified and can be stored in the same manner as active enzyme preparations.

The active site mutants also provide a tool with which to investigate further the structural and functional properties of this unique protease, beyond the enzymatic activity.

#### EXAMPLES

The following Examples are included solely to provide a more complete understanding of the subject invention. The Examples do not limit the scope of the invention described and claimed herein in any fashion.

## Generation of the Constructs:

### **Example 1a: Construction of Human $\beta$ -I Tryptase Expression Vector:**

5 The 5' and 3' ends of the human  $\beta$ -I tryptase gene encoded by pBSHumTry (see *Vanderslice et al.*, 1990) were modified via PCR using a pair of partially homologous oligonucleotide primers, SEQ. ID NO. 2 and SEQ. ID NO. 3. The modified tryptase fragment was ligated to the *Xho* I and *Not* I sites of pPIC9 (Invitrogen) downstream of the  $\alpha$ -Factor secretion signal found on pPIC9 (see "S" in Fig. 2) to yield an expression construct designated pPIC9-HumTry. *E. coli* strain JM109 (Promega Corporation, Madison, Wisconsin, U.S.A.) was transformed with the ligation mix using standard protocols (calcium chloride) to form a library of transformants. Transformants were screened for properly constructed pPIC9-HumTry constructs by restriction analysis of the plasmid DNA isolated from ampicillin-resistant colonies.

### **Example 1b: Construction of Human $\beta$ -II Tryptase Expression Vector:**

15 Amino acid 102 of human  $\beta$ -I tryptase in pPIC9-HumTry was mutated from asparagine to lysine, changing the protein from human  $\beta$ -I tryptase to human  $\beta$ -II tryptase. The gene was mutated with the GeneEditor *in vitro* Site Directed Mutagenesis Kit (Promega Corporation), following the kit directions. The oligonucleotide used for this mutation was SEQ. ID. NO. 7, described above.

20 The mutation reaction was used to transform bacterial strain BMH71-18. Other strains containing a transposon insertion in the mutS gene, such as ES1301, can be used with equal success. DNA was isolated from the cells and was used to transform JM109 *E. coli* cells. DNA isolated from the JM109 cells was digested with restriction enzymes to confirm the mutagenesis of amino acid 102.

### Example 1c: Construction of H44A, D91A and S194A Mutants:

For both  $\beta$ -I and  $\beta$ -II tryptase genes, mutant constructs were generated, with each one having a mutation in one of the three putative active sites. Each of the mutations changed the amino acid residue to alanine.

Using the QuikChange™ Site Directed Mutagenesis Kit (Stratagene, La Jolla, California), site-directed mutagenesis was performed. Top and bottom strand oligos were paired for each amino acid. For the S194A mutation one pair of oligos was predicted to form a loop structure. Thus, two pairs of oligos (one predicted to form the loop structure and one, not) were tested separately. Both the pPIC9-HumTry ( $\beta$ -I tryptase) plasmid and the pPIC9-HumTry N102K ( $\beta$ -II tryptase) plasmids were mutated at three of the putative active sites. A separate mutant was generated for each site.

The following oligonucleotides were used for mutagenesis:

SEQ. ID. NO. 12, top strand for H44A:

(5'-GTGCTGACCGCCGCGGCGTGCGTGGGACCGGAC-3');

SEQ. ID. NO. 13, bottom strand for H44A:

(5'-GTCCGGTCCCACGCACGCCGCGGCGGTCAGCAC-3');

SEQ. ID. NO. 14, top strand for D91A:

(5'-GCCCAGATCGGAGCGGCAATCGCCCTGCTGGAG-3');

SEQ. ID. NO. 15, bottom strand for D91A:

(5'-CTCCAGCAGGGCGATTGCCGCTCCGATCTGGGC-3');

SEQ. ID. NO. 16, first top strand for S194A, which formed a loop at 44 °C:

(5'-TGTCAAGGCGACGCCGGCGGACCTCTGGTG-3');

SEQ. ID. NO. 17, first bottom strand for S194A:

(5'-CACCAGAGGTCCGCCGGCGTGCCTTGACA-3');

SEQ. ID. NO. 18, second top strand for S194A, which did not form a loop:

(5'-CAAGGAGACGCCGGCGGACCACTGGTGT-3'); and

SEQ. ID. NO. 19, second bottom strand for S194A:

(5'-GCACACCAGGGGCCCCGCCGGCGTCGCCCTGGCATGA-3').

The mutants generated with the oligos above had the sequences shown in Table 1:

SEQ. ID. NO.	Description
20	$\beta$ -II DNA for active site mutant H44A pre-cleavage
21	$\beta$ -II amino acid for active site mutant H44A pre-cleavage
22	$\beta$ -II DNA for active site mutant D91A pre-cleavage
23	$\beta$ -II amino acid for active site mutant D91A pre-cleavage
24	$\beta$ -II DNA for active site mutant S194A pre-cleavage (+loop)
25	$\beta$ -II amino acid for active site mutant S194A pre-cleavage
26	$\beta$ -II DNA for active site mutant S194A pre-cleavage (- loop)
27	$\beta$ -II amino acid for active site mutant S194A pre-cleavage
28	$\beta$ -II DNA for active site mutant H44A mature
29	$\beta$ -II amino acid for active site mutant H44A mature
30	$\beta$ -II DNA for active site mutant D91A mature
31	$\beta$ -II amino acid for active site mutant D91A mature
32	$\beta$ -II DNA for active site mutant S194A mature (+loop)
33	$\beta$ -II amino acid for active site mutant S194A mature (+loop)
34	$\beta$ -II DNA for active site mutant S194A mature (- loop)
35	$\beta$ -II amino acid for active site mutant S194A mature (- loop)
36	$\beta$ -I DNA for active site mutant H44A pre-cleavage
37	$\beta$ -I amino acid for active site mutant H44A pre-cleavage
38	$\beta$ -I DNA for active site mutant D91A pre-cleavage
39	$\beta$ -I amino acid for active site mutant D91A pre-cleavage

40	$\beta$ -I DNA for active site mutant S194A pre-cleavage (+loop)
41	$\beta$ -I amino acid for active site mutant S194A pre-cleavage
42	$\beta$ -I DNA for active site mutant S194A pre-cleavage (- loop)
43	$\beta$ -I amino acid for active site mutant S194A pre-cleavage
44	$\beta$ -I DNA for active site mutant H44A mature
45	$\beta$ -I amino acid for active site mutant H44A mature
46	$\beta$ -I DNA for active site mutant D91A mature
47	$\beta$ -I amino acid for active site mutant D91A mature
48	$\beta$ -I DNA for active site mutant S194A mature (+loop)
49	$\beta$ -I amino acid for active site mutant S194A mature (+loop)
50	$\beta$ -I DNA for active site mutant S194A mature (- loop)
51	$\beta$ -I amino acid for active site mutant S194A mature (- loop)

All mutants were transformed into the cells included in the QuikChange Kit: Epicurian Coli<sup>®</sup> XL1-Blue supercompetent cells. Kit instructions were followed with the following exceptions. The pPIC9HumTryN102K plasmid template was used at 16, 32, and 64 ng per reaction. Also, the reaction was cycled as described in the kit, except that the last extension was 18 minutes at 68°C.

Epicurian Coli<sup>®</sup> XL1-Blue supercompetent cells were transformed with the mutation reactions. From each mutation, nine colonies were picked and grown overnight in LB with 100  $\mu$ g/ml ampicillin. Plasmids were isolated using Wizard S/V (Promega, Madison, Wisconsin). To confirm the mutations, restriction enzyme digests were conducted in 20  $\mu$ l final volume with 5  $\mu$ l of each DNA using *Sac* I or *Nae* I Turbo. DNA was then sequenced to verify the mutations.

## Transformation of *Pichia pastoris* with the Constructs:

### **Example 2a: Human $\beta$ -I Tryptase:**

Fresh cultures of *Pichia pastoris* strains GS115 (ATCC 20864) and KM71 (Invitrogen) were prepared for electroporation by extensive washing with 1M Sorbitol. Electrocompetent cells were mixed with aliquots of pPIC9-HumTry DNA produced according to Example 1a that had been digested with one of either *Sal* I, *Bgl* II, or *Sac* I, and transformed. Transformants were initially identified as *His*<sup>+</sup> prototrophs on minimal media. Methanol utilization phenotypes were analyzed via replica plating on both minimal dextrose and minimal methanol grid plates.

### **Example 2b: Human $\beta$ -II Tryptase:**

The pPIC9-HumTryN102K DNA was digested with *Sal* I. The digestion was incubated for 90 minutes at 37°C, and was stopped by incubating the mix at 65°C. The mixture was then ethanol precipitated, and the pellet was resuspended in 50  $\mu$ l of water.

*Pichia* cells (SMD1168, Invitrogen; GS115, ATCC 20864; and KM71, Invitrogen) were transformed with the DNA by electroporation with the following protocol. Cuvettes were prechilled in the refrigerator. 80  $\mu$ l of electrocompetent cells were transferred to the cuvettes. 10  $\mu$ l of the *Sal* I cut DNA was added. The cells were pulsed according to the following parameters: gap equals 0.2 cm, voltage equals 1,500 volts, capacitance equals 25  $\mu$ F, and resistance equals 200  $\Omega$ . One ml of prechilled 1M sorbitol was added. 200  $\mu$ l of electroporated cells was spread on minimal dextrose plates. The plates were incubated at 30°C.

*Pichia* clones were screened for Mut<sup>+</sup> and Mut<sup>S</sup> transformants as described in the Invitrogen *Pichia* Expression Manual.

### Example 2c: H44A, D91A and S194A Mutants

The active site mutants were partially cut with *Sac* I. *P. pastoris* GS115 were transformed with the partially-cut active site constructs by electroporation and screened as is described in Example 2b.

5

### Western Blot Analysis

#### Example 3a: Human $\beta$ -I and $\beta$ -II Tryptases

Glycosidase digestions with PGNase F were performed on  $\beta$ -I and  $\beta$ -II tryptases. **Fig. 3** is a Western blot of  $\beta$ -I tryptase (rh  $\beta$  I) ;  $\beta$ -II tryptase (rh  $\beta$  II), and  $\beta$ -tryptase isolated from a cadaver (native  $\beta$ ). The transferred tryptase was visualized by probing with biotinylated anti-human tryptase AA5 monoclonal antibody (Promega Corporation). The undigested tryptases (see the first three lanes) were compared to the digested tryptases (see the second three lanes). As shown in **Fig. 3**, the glycosidase digestion yields a single tryptase core protein for the recombinant proteolytic tryptases. Note the presence of likely degradation products of native tryptase.

10

15

Recombinant  $\beta$ -I tryptase, recombinant  $\beta$ -II tryptase, and cadaveric lung tryptase were loaded onto a COOMASSIE<sup>®</sup>-stained SDS PAGE to show the glycosylation status of the proteins. Referring to **Fig. 4**, the  $\beta$ -II tryptase generated from pPIC9-HumTryN102K has one less glycosylation site than recombinant  $\beta$ -I tryptase. When digested with either PNGase F or Endo H, the  $\beta$ -II tryptase generated from pPIC9-HumTryN102K behaves like  $\beta$ -I tryptase derived from pPIC9-HumTry tryptase (reduced to 1 core) (data not shown). Cadaveric tryptase is not digested by addition of Endo H (data not shown).

20

25

### **Example 3b: H44A, D91A, and S194A Mutants**

5 **Fig. 5** is a Western blot of *Pichia pastoris* fermentation induction of  $\beta$ -I trypsin and two of its active site mutants (H44A and S194A). The gel was visualized by probing with biotinylated anti-human trypsin AA5 monoclonal antibody (Promega Corporation). Although glycosylation studies were not performed on the active site mutants, as is shown in **Fig. 5**, the active site mutants migrated at the same molecular weights as their active counterparts.

### **Enzyme Assay (with Unpurified Enzyme)**

#### **Example 4a: Human $\beta$ -I Trypsin and H44A and S194A Mutants Thereof:**

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1215  
1220  
1225  
1230  
1235  
1240  
1245  
1250  
1255  
1260  
1265  
1270  
1275  
1280  
1285  
1290  
1295  
1300  
1305  
1310  
1315  
1320  
1325  
1330  
1335  
1340  
1345  
1350  
1355  
1360  
1365  
1370  
1375  
1380  
1385  
1390  
1395  
1400  
1405  
1410  
1415  
1420  
1425  
1430  
1435  
1440  
1445  
1450  
1455  
1460  
1465  
1470  
1475  
1480  
1485  
1490  
1495  
1500  
1505  
1510  
1515  
1520  
1525  
1530  
1535  
1540  
1545  
1550  
1555  
1560  
1565  
1570  
1575  
1580  
1585  
1590  
1595  
1600  
1605  
1610  
1615  
1620  
1625  
1630  
1635  
1640  
1645  
1650  
1655  
1660  
1665  
1670  
1675  
1680  
1685  
1690  
1695  
1700  
1705  
1710  
1715  
1720  
1725  
1730  
1735  
1740  
1745  
1750  
1755  
1760  
1765  
1770  
1775  
1780  
1785  
1790  
1795  
1800  
1805  
1810  
1815  
1820  
1825  
1830  
1835  
1840  
1845  
1850  
1855  
1860  
1865  
1870  
1875  
1880  
1885  
1890  
1895  
1900  
1905  
1910  
1915  
1920  
1925  
1930  
1935  
1940  
1945  
1950  
1955  
1960  
1965  
1970  
1975  
1980  
1985  
1990  
1995  
2000  
2005  
2010  
2015  
2020  
2025  
2030  
2035  
2040  
2045  
2050  
2055  
2060  
2065  
2070  
2075  
2080  
2085  
2090  
2095  
2100  
2105  
2110  
2115  
2120  
2125  
2130  
2135  
2140  
2145  
2150  
2155  
2160  
2165  
2170  
2175  
2180  
2185  
2190  
2195  
2200  
2205  
2210  
2215  
2220  
2225  
2230  
2235  
2240  
2245  
2250  
2255  
2260  
2265  
2270  
2275  
2280  
2285  
2290  
2295  
2300  
2305  
2310  
2315  
2320  
2325  
2330  
2335  
2340  
2345  
2350  
2355  
2360  
2365  
2370  
2375  
2380  
2385  
2390  
2395  
2400  
2405  
2410  
2415  
2420  
2425  
2430  
2435  
2440  
2445  
2450  
2455  
2460  
2465  
2470  
2475  
2480  
2485  
2490  
2495  
2500  
2505  
2510  
2515  
2520  
2525  
2530  
2535  
2540  
2545  
2550  
2555  
2560  
2565  
2570  
2575  
2580  
2585  
2590  
2595  
2600  
2605  
2610  
2615  
2620  
2625  
2630  
2635  
2640  
2645  
2650  
2655  
2660  
2665  
2670  
2675  
2680  
2685  
2690  
2695  
2700  
2705  
2710  
2715  
2720  
2725  
2730  
2735  
2740  
2745  
2750  
2755  
2760  
2765  
2770  
2775  
2780  
2785  
2790  
2795  
2800  
2805  
2810  
2815  
2820  
2825  
2830  
2835  
2840  
2845  
2850  
2855  
2860  
2865  
2870  
2875  
2880  
2885  
2890  
2895  
2900  
2905  
2910  
2915  
2920  
2925  
2930  
2935  
2940  
2945  
2950  
2955  
2960  
2965  
2970  
2975  
2980  
2985  
2990  
2995  
3000  
3005  
3010  
3015  
3020  
3025  
3030  
3035  
3040  
3045  
3050  
3055  
3060  
3065  
3070  
3075  
3080  
3085  
3090  
3095  
3100  
3105  
3110  
3115  
3120  
3125  
3130  
3135  
3140  
3145  
3150  
3155  
3160  
3165  
3170  
3175  
3180  
3185  
3190  
3195  
3200  
3205  
3210  
3215  
3220  
3225  
3230  
3235  
3240  
3245  
3250  
3255  
3260  
3265  
3270  
3275  
3280  
3285  
3290  
3295  
3300  
3305  
3310  
3315  
3320  
3325  
3330  
3335  
3340  
3345  
3350  
3355  
3360  
3365  
3370  
3375  
3380  
3385  
3390  
3395  
3400  
3405  
3410  
3415  
3420  
3425  
3430  
3435  
3440  
3445  
3450  
3455  
3460  
3465  
3470  
3475  
3480  
3485  
3490  
3495  
3500  
3505  
3510  
3515  
3520  
3525  
3530  
3535  
3540  
3545  
3550  
3555  
3560  
3565  
3570  
3575  
3580  
3585  
3590  
3595  
3600  
3605  
3610  
3615  
3620  
3625  
3630  
3635  
3640  
3645  
3650  
3655  
3660  
3665  
3670  
3675  
3680  
3685  
3690  
3695  
3700  
3705  
3710  
3715  
3720  
3725  
3730  
3735  
3740  
3745  
3750  
3755  
3760  
3765  
3770  
3775  
3780  
3785  
3790  
3795  
3800  
3805  
3810  
3815  
3820  
3825  
3830  
3835  
3840  
3845  
3850  
3855  
3860  
3865  
3870  
3875  
3880  
3885  
3890  
3895  
3900  
3905  
3910  
3915  
3920  
3925  
3930  
3935  
3940  
3945  
3950  
3955  
3960  
3965  
3970  
3975  
3980  
3985  
3990  
3995  
4000  
4005  
4010  
4015  
4020  
4025  
4030  
4035  
4040  
4045  
4050  
4055  
4060  
4065  
4070  
4075  
4080  
4085  
4090  
4095  
4100  
4105  
4110  
4115  
4120  
4125  
4130  
4135  
4140  
4145  
4150  
4155  
4160  
4165  
4170  
4175  
4180  
4185  
4190  
4195  
4200  
4205  
4210  
4215  
4220  
4225  
4230  
4235  
4240  
4245  
4250  
4255  
4260  
4265  
4270  
4275  
4280  
4285  
4290  
4295  
4300  
4305  
4310  
4315  
4320  
4325  
4330  
4335  
4340  
4345  
4350  
4355  
4360  
4365  
4370  
4375  
4380  
4385  
4390  
4395  
4400  
4405  
4410  
4415  
4420  
4425  
4430  
4435  
4440  
4445  
4450  
4455  
4460  
4465  
4470  
4475  
4480  
4485  
4490  
4495  
4500  
4505  
4510  
4515  
4520  
4525  
4530  
4535  
4540  
4545  
4550  
4555  
4560  
4565  
4570  
4575  
4580  
4585  
4590  
4595  
4600  
4605  
4610  
4615  
4620  
4625  
4630  
4635  
4640  
4645  
4650  
4655  
4660  
4665  
4670  
4675  
4680  
4685  
4690  
4695  
4700  
4705  
4710  
4715  
4720  
4725  
4730  
4735  
4740  
4745  
4750  
4755  
4760  
4765  
4770  
4775  
4780  
4785  
4790  
4795  
4800  
4805  
4810  
4815  
4820  
4825  
4830  
4835  
4840  
4845  
4850  
4855  
4860  
4865  
4870  
4875  
4880  
4885  
4890  
4895  
4900  
4905  
4910  
4915  
4920  
4925  
4930  
4935  
4940  
4945  
4950  
4955  
4960  
4965  
4970  
4975  
4980  
4985  
4990  
4995  
5000  
5005  
5010  
5015  
5020  
5025  
5030  
5035  
5040  
5045  
5050  
5055  
5060  
5065  
5070  
5075  
5080  
5085  
5090  
5095  
5100  
5105  
5110  
5115  
5120  
5125  
5130  
5135  
5140  
5145  
5150  
5155  
5160  
5165  
5170  
5175  
5180  
5185  
5190  
5195  
5200  
5205  
5210  
5215  
5220  
5225  
5230  
5235  
5240  
5245  
5250  
5255  
5260  
5265  
5270  
5275  
5280  
5285  
5290  
5295  
5300  
5305  
5310  
5315  
5320  
5325  
5330  
5335  
5340  
5345  
5350  
5355  
5360  
5365  
5370  
5375  
5380  
5385  
5390  
5395  
5400  
5405  
5410  
5415  
5420  
5425  
5430  
5435  
5440  
5445  
5450  
5455  
5460  
5465  
5470  
5475  
5480  
5485  
5490  
5495  
5500  
5505  
5510  
5515  
5520  
5525  
5530  
5535  
5540  
5545  
5550  
5555  
5560  
5565  
5570  
5575  
5580  
5585  
5590  
5595  
5600  
5605  
5610  
5615  
5620  
5625  
5630  
5635  
5640  
5645  
5650  
5655  
5660  
5665  
5670  
5675  
5680  
5685  
5690  
5695  
5700  
5705  
5710  
5715  
5720  
5725  
5730  
5735  
5740  
5745  
5750  
5755  
5760  
5765  
5770  
5775  
5780  
5785  
5790  
5795  
5800  
5805  
5810  
5815  
5820  
5825  
5830  
5835  
5840  
5845  
5850  
5855  
5860  
5865  
5870  
5875  
5880  
5885  
5890  
5895  
5900  
5905  
5910  
5915  
5920  
5925  
5930  
5935  
5940  
5945  
5950  
5955  
5960  
5965  
5970  
5975  
5980  
5985  
5990  
5995  
6000  
6005  
6010  
6015  
6020  
6025  
6030  
6035  
6040  
6045  
6050  
6055  
6060  
6065  
6070  
6075  
6080  
6085  
6090  
6095  
6100  
6105  
6110  
6115  
6120  
6125  
6130  
6135  
6140  
6145  
6150  
6155  
6160  
6165  
6170  
6175  
6180  
6185  
6190  
6195  
6200  
6205  
6210  
6215  
6220  
6225  
6230  
6235  
6240  
6245  
6250  
6255  
6260  
6265  
6270  
6275  
6280  
6285  
6290  
6295  
6300  
6305  
6310  
6315  
6320  
6325  
6330  
6335  
6340  
6345  
6350  
6355  
6360  
6365  
6370  
6375  
6380  
6385  
6390  
6395  
6400  
6405  
6410  
6415  
6420  
6425  
6430  
6435  
6440  
6445  
6450  
6455  
6460  
6465  
6470  
6475  
6480  
6485  
6490  
6495  
6500  
6505  
6510  
6515  
6520  
6525  
6530  
6535  
6540  
6545  
6550  
6555  
6560  
6565  
6570  
6575  
6580  
6585  
6590  
6595  
6600  
6605  
6610  
6615  
6620  
6625  
6630  
6635  
6640  
6645  
6650  
6655  
6660  
6665  
6670  
6675  
6680  
6685  
6690  
6695  
6700  
6705  
6710  
6715  
6720  
6725  
6730  
6735  
6740  
6745  
6750  
6755  
6760  
6765  
6770  
6775  
6780  
6785  
6790  
6795  
6800  
6805  
6810  
6815  
6820  
6825  
6830  
6835  
6840  
6845  
6850  
6855  
6860  
6865  
6870  
6875  
6880  
6885  
6890  
6895  
6900  
6905  
6910  
6915  
6920  
6925  
6930  
6935  
6940  
6945  
6950  
6955  
6960  
6965  
6970  
6975  
6980  
6985  
6990  
6995  
7000  
7005  
7010  
7015  
7020  
7025  
7030  
7035  
7040  
7045  
7050  
7055  
7060  
7065  
7070  
7075  
7080  
7085  
7090  
7095  
7100  
7105  
7110  
7115  
7120  
7125  
7130  
7135  
7140  
7145  
7150  
7155  
7160  
7165  
7170  
7175  
7180  
7185  
7190  
7195  
7200  
7205  
7210  
7215  
7220  
7225  
7230  
7235  
7240  
7245  
7250  
7255  
7260  
7265  
7270  
7275  
7280  
7285  
7290  
7295  
7300  
7305  
7310  
7315  
7320  
7325  
7330  
7335  
7340  
7345  
7350  
7355  
7360  
7365  
7370  
7375  
7380  
7385  
7390  
7395  
7400  
7405  
7410  
7415  
7420  
7425  
7430  
7435  
7440  
7445  
7450  
7455  
7460  
7465  
7470  
7475  
7480  
7485  
7490  
7495  
7500  
7505  
7510  
7515  
7520  
7525  
7530  
7535  
7540  
7545  
7550  
7555  
7560  
7565  
7570  
7575  
7580  
7585  
7590  
7595  
7600  
7605  
7610  
7615  
7620  
7625  
7630  
7635  
7640  
7645  
7650  
7655  
7660  
7665  
7670  
7675  
7680  
7685  
7690  
7695  
7700  
7705  
7710  
7715  
7720  
7725  
7730  
7735  
7740  
7745  
7750  
7755  
7760  
7765  
7770  
7775  
7780  
7785  
7790  
7795  
7800  
7805  
7810  
7815  
7820  
7825  
7830  
7835  
7840  
7845  
7850  
7855  
7860  
7865  
7870  
7875  
7880  
7885  
7890  
7895  
7900  
7905  
7910  
7915  
7920  
7925  
7930  
7935  
7940  
7945  
7950  
7955  
7960  
7965  
7970  
7975  
7980  
7985  
7990  
7995  
8000  
8005  
8010  
8015  
8020  
8025  
8030  
8035  
8040  
8045  
8050  
8055  
8060  
8065  
8070  
8075  
8080  
8085  
8090  
8095  
8100  
8105  
8110  
8115  
8120  
8125  
8130  
8135  
8140  
8145  
8150  
8155  
8160  
8165  
8170  
8175  
8180  
8185  
8190  
8195  
8200  
8205  
8210  
8215  
8220  
8225  
8230  
8235  
8240  
8245  
8250  
8255  
8260  
8265  
8270  
8275  
8280  
8285  
8290  
8295  
8300  
8305  
8310  
8315  
8320  
8325  
8330  
8335  
8340  
8345  
8350  
8355  
8360  
8365  
8370  
8375  
8380  
8385  
8390  
8395  
8400  
8405  
8410  
8415  
8420  
8425  
8430  
8435  
8440  
8445  
8450  
8455  
8460  
8465  
8470  
8475  
8480  
8485  
8490  
8495  
8500  
8505  
8510  
8515  
8520  
8525  
8530  
8535  
8540  
8545  
8550  
8555  
8560  
8565  
8570  
8575  
8580  
8585  
8590  
8595  
8600  
8605  
8610  
8615  
8620  
8625  
8630  
8635  
8640  
8645  
8650  
8655  
8660  
8665  
8670  
8675  
8680  
8685  
8690  
8695  
8700  
8705  
8710  
8715  
8720  
8725  
8730  
8735  
8740  
8745  
8750  
8755  
8760  
8765  
8770  
8775  
8780  
8785  
8790  
8795  
8800  
8805  
8810  
8815  
8820  
8825  
8830  
8835  
8840  
8845  
8850  
8855  
8860  
8865  
8870  
8875  
8880  
8885  
8890  
8895  
8900  
8905  
8910  
8915  
8920  
8925  
8930  
8935  
8940  
8945  
8950  
8955  
8960  
8965  
8970  
8975  
8980  
8985  
8990  
8995  
9000  
9005  
9010  
9015  
9020  
9025  
9030  
9035  
9040  
9045  
9050  
9055  
9060  
9065  
9070  
9075  
9080  
9085  
9090  
9095  
9100  
9105  
9110  
9115  
9120  
9125  
9130  
9135  
9140  
9145  
9150  
9155  
9160  
9165  
9170  
9175  
9180  
9185  
9190  
9195  
9200  
9205  
9210  
9215  
9220  
9225  
9230  
9235  
9240  
9245  
9250  
9255  
9260  
9265  
9270  
9275  
9280  
9285  
9290  
9295  
9300  
9305  
9310  
9315  
9320  
9325  
9330  
9335  
9340  
9345  
9350  
9355  
9360  
9365  
9370  
9375  
9380  
9385  
9390  
9395  
9400  
9405  
9410  
9415  
9420  
9425  
9430  
9435  
9440  
9445  
9450  
9455  
9460  
9465  
9470  
9475  
9480  
9485  
9490  
9495  
9500  
9505  
9510  
9515  
9520  
9525  
9530  
9535  
9540  
9545  
9550  
9555  
9560  
9565  
9570  
9575  
9580  
9585  
9590  
9595  
9600  
9605  
9610  
9615  
9620  
9625  
9630  
9635  
9640  
9645  
9650  
9655  
9660  
9665  
9670  
9675  
9680  
9685  
9690  
9695  
9700  
9705  
9710  
9715  
9720  
9725  
9730  
9735  
9740  
9745  
9750  
9755  
9760  
9765  
9770  
9775  
9780  
9785  
9790  
9795  
9800  
9805  
9810  
9815  
9820  
9825  
9830  
9835  
9840  
9845  
9850  
9855  
9860  
9865  
9870  
9875  
9880  
9885  
9890  
9895  
9900  
9905  
9910  
9915  
9920  
9925  
9930  
9935  
9940  
9945  
9950  
9955  
9960  
9965  
9970  
9975  
9980  
9985  
9990  
9995  
10000  
10005  
10010  
10015  
10020  
10025  
10030  
10035  
10040  
10045  
10050  
10055  
10060  
10065  
10070  
10075  
10080  
10085  
10090  
10095  
10100  
10105  
10110  
10115  
10120  
10125  
10130  
10135  
10140  
10145  
10150  
10155  
10

## Tryptase Purification Scheme

### **Example 5: Purification of Recombinant Proteolytic Tryptases:**

The following example was performed on a  $\beta$ -I tryptase clone. This purification scheme was also used on  $\beta$ -II tryptase and active site mutations of both  $\beta$ -I and  $\beta$ -II tryptase.

The *Pichia pastoris* clone expressing  $\beta$ -I tryptase was grown in BMMY medium in a fermentor at 30°C with a stirring rate of 250 revolutions per minute. The pH of the medium was maintained at 5.0-5.1 and expression was induced by the addition of methanol to 0.5% (v/v). After 72 h. the cell-free medium was collected by centrifugation at 400 g to pellet the cells, then stored at -70°C. Purification of  $\beta$ -I tryptase was begun with 112 ml of cell-free medium containing  $\beta$ -I tryptase, which was thawed at 37°C in a shaking incubator and assayed for activity. All subsequent enzyme purification steps were conducted at room temperature. Established hydrophobic and heparin-binding properties of cadaveric human lung tryptase were exploited to devise a simple scheme for the affinity purification of  $\beta$ -I tryptase. The supernatant was made 2.0 M in  $(\text{NH}_4)_2\text{SO}_4$  by slowly adding solid with magnetic stirring over a 30 minute period. After centrifugation at 20,000 g for 15 minute the supernatant was sampled and assayed for activity. The supernatant containing 2 M  $(\text{NH}_4)_2\text{SO}_4$  was then mixed with a 60 ml bed volume of Toyopearl butyl 650 M hydrophobic interaction gel matrix pre-equilibrated with 10 mM Mes/2 M  $(\text{NH}_4)_2\text{SO}_4$ /0.5 M NaCl/10% (v/v) glycerol/0.02%  $\text{NaN}_3$  (pH 6.1). This mixture was shaken gently at room temperature for 1 hour to allow binding of the enzyme.

Periodically the gel matrix supernatant was sampled and assayed to determine binding efficiency. When no appreciable activity remained unbound, the resin was loaded in a column and washed with 1 liter of pre-equilibration buffer. The bound protein was eluted from the column by the

addition of 10 mM Mes/0.2 M NaCl/10% (v/v) glycerol/0.02% NaN<sub>3</sub> (pH 5.5). Fractions (5 ml) were collected and assayed for activity, and those containing more than 2 units/ml were pooled. Although several non-tryptase proteins, including a green *Pichia* pigment, were co-purified during butyl column chromatography, this step served to concentrate the  $\beta$ -I tryptase activity while removing residual components in the *Pichia* fermentation medium. Active fractions from the butyl column were pooled, assayed, diluted 1:2 in nanopure water to reduce the salt concentration and mixed with a 60 ml bed volume of Toyopearl AF-Heparin 650 M, pre-equilibrated with 10 mM Mes/0.2 M NaCl/10% (v/v) glycerol/0.02% NaN<sub>3</sub> (pH 5.5).

During a 1 hour incubation at room temperature the supernatant was assayed periodically to determine binding efficiency. When no appreciable activity remained unbound, the resin was loaded in a column and washed with 1 liter of pre-equilibration buffer. Enzyme elution was achieved with 10 mM Mes/2 M NaCl/10% (v/v) glycerol/0.02% NaN<sub>3</sub> (pH 6.1). Fractions (5 ml) were collected and those containing at least 2 units/ml activity were pooled. After assay for activity, the  $\beta$ -I tryptase was dialysed and concentrated with an AMICON-brand stirred-cell concentrator equipped with a 10 kDa cut-off membrane. The purified  $\beta$ -I tryptase was stored in the heparin column elution buffer.

The heparin affinity column provided the greatest enrichment of  $\beta$ -I tryptase activity. An SDS/PAGE analysis of the purified  $\beta$ -I tryptase showed that the purified  $\beta$ -I tryptase contained two major bands with estimated molecular masses of 35,900 and 34,200 Da, a faint band at 33,000 Da and a diffuse region at approximately 50,000 Da. Image analysis of band intensities and areas showed that the two major bands accounted for more than 90% of the total reactive protein. The specific activity of the purified  $\beta$ -I tryptase was consistently greater than 1000 units/mg by an  $\alpha$ -N-

benzyloxycarbonyl-lysine thiobenzyl ester cleavage assay, which was approximately twice that of pure, fully active natural cadaveric human lung tryptase. The concentration of  $\beta$ -I tryptase was calculated by taking 27,500 Da as the molecular mass of the unglycosylated protein subunits, and a  $A_{280}$  (1%) of 28.1 as determined for pure cadaveric human lung tryptase. Active-site titrations with the fluorescent 4-methylumbelliferyl *p*-guanidinobenzoate titrant showed that two preparations of  $\beta$ -I tryptase contained 94% and 96% active subunits. Two preparations of cadaveric human lung tryptase titrated at the same time contained 88% and 96% active sites.

### Enzyme Assay (with Purified Enzyme)

#### **Example 6a: Human $\beta$ -I Tryptase**

In this Example, the yield and activity of purified tryptase from a 112 ml sample of media from a fermentation of the  $\beta$ -I tryptase clone GS115/HumTry 5-37 is presented. Specific activity was determined by the CBZ-Lys-S-Thiobenzyl Ester/DNTB coupled cleavage assay. Table 2 summarizes the results. This Example demonstrates the ease of purification and high recovery of tryptase using the subject invention:

**Table 2: Purification Data from 112 ml conditioned media preparation**

Step	Total Protein ( $A_{280}$ )	Total Activity (Units)	Specific Activity (Units/mg)	Yield (%)
Media: raw supernatant	3424	732	0.21	100
Butyl HIC resin	68.7	721	10.5	98.5
Heparin resin	0.69	817	1177	111

### Example 6b: Active Site Mutants of $\beta$ -I and $\beta$ -II Trypsin

Purified trypsin from  $\beta$ -I trypsin and  $\beta$ -II trypsin and their respective S194A active site mutants were assayed by CBZ-Lys-Thiobenzyl Ester/DNTB assay. Results showed that the  $\beta$ -I and  $\beta$ -II trypsin had activity, whereas active site mutants of  $\beta$ -I and  $\beta$ -II trypsin had minimal or no activity, suggesting that the amino acids 44, 91, and 194 were imperative for proteolytic trypsin activity.

The specific cleavage activity of purified enzyme from both  $\beta$ -I and  $\beta$ -II trypsin and active site mutants thereof were determined by CBZ-Lys-Thiobenzyl Ester/DNTB assay. Table 3 summarizes the results.

**Table 3: Specific Activity of Proteolytic Trypsins ( $\beta$ -I and  $\beta$ -II) and S194A Active Site Mutants Thereof:**

Proteolytic Trypsin	Specific Activity (U/mg)
$\beta$ -I	1300
$\beta$ -I S194A active site mutant	1.85
$\beta$ -II	1950
$\beta$ -II S194A active site mutant	1.1

Clearly, the results shown in Table 3 show the obliteration of the specific cleavage activity due to the active site mutations.

To verify that expressed trypsin active site mutants lacked activity due to the active site mutations and not to a lack of expression, SDS-PAGE were run on the active site mutants (H44A and S194A) of  $\beta$ -I trypsin and the enzymatically-active form of recombinant  $\beta$ -I trypsin. Proteins were transferred to membranes and blotted with biotinylated anti-human trypsin AA5 monoclonal antibody (Promega Corporation), as described above. Fig. 5 shows the Western blot results of this study, which demonstrates that

the active site mutants express tryptase protein. Thus, the lack of specific activity in these mutants is due to the mutation of the active sites and not due to a lack of protein production.

5 **Example 6c: Comparison of Kinetics Between Recombinant  $\beta$ -I Tryptase and Human Cadaveric Tryptase:**

In this Example, the kinetics of the recombinant human  $\beta$ -I tryptase according to the present invention (rHT) were compared to the kinetics of cadaveric human tryptase isolated from lung (HLT). The results are shown in Table 4:

10 **Table 4: Kinetic Data - rHT v. HLT:**

	$K_m$ ( $\mu M$ )	$k_{cat}$ ( $S^{-1}$ )	$k_{cat}/K_m$ ( $M^{-1} S^{-1}$ )
rHT ( $\beta$ -I) (pPIC9-HumTry)	67	110	$1.64 \times 10^6$
HLT (cadaveric)	55	46	$0.84 \times 10^6$

15 **Example 6d:  $K_m$  Determination of the Recombinant  $\beta$ -I and  $\beta$ -II Tryptase:**

The  $K_m$  of the recombinant  $\beta$ -I and  $\beta$ -II tryptase isoforms were determined by both the Lineweaver-Burk Plot (LBP) and the Eadie-Hofstee Plot (EHP). The values obtained were : tryptase  $\beta$ -I =  $36 \mu M$  (LBP) and  $24.5 \mu M$  (EHP); and  $\beta$ -II tryptase =  $30 \mu M$  (LBP) and  $29.1 \mu M$  (EHP).

20 **Gel Filtration Assay**

25 **Example 7: Gel Filtration of  $\beta$ -I and  $\beta$ -II Tryptases and a  $\beta$ -I Tryptase Active Site Mutant:**

Gel filtration analysis of the  $\beta$ -I and  $\beta$ -II tryptases and a  $\beta$ -I tryptase active site mutant was conducted to confirm further the tetrameric structure

of these recombinant homomeric enzymes. Fig. 7 shows that the  $\beta$ -I and  $\beta$ -II tryptases and the S194A  $\beta$ -I tryptase active site mutant all have the same molecular weight, confirming that all were tetramers. Because there are no known natural physiological inhibitors of tryptase, the enzymes are thought to be regulated by disassociation from the active tetrameric form to the inactive disassociation products. See Schwartz L. and Bradford T. (1986). Therefore, it was important to correlate the  $\beta$ -I and  $\beta$ -II tryptase activity to the tetrameric form as well as to confirm that the mutation introduced in the  $\beta$ -I tryptase effected the enzyme's catalytic site, not its ability to form a tetramer.

**Inhibition Assay:**

**Example 8a:  $\beta$ -I and  $\beta$ -II Tryptase Inhibition with AEBSF:**

A study was done to determine whether AEBSF (A.G. Scientific Inc., San Diego, California), an inhibitor of serine proteases, inhibits recombinant human  $\beta$ -I and  $\beta$ -II tryptase and to determine if there were any inhibition differences between the two isoforms.

Samples of  $\beta$ -I and  $\beta$ -II tryptase at 200  $\mu$ g/ml were treated with either 0.1 mM or 1.0 mM (final) AEBSF in water and monitored after a 60 minute period by the CBZ-Lys-Thiobenzyl Ester/DNTB coupled cleavage assay.

As Fig. 8 shows, AEBSF is a very potent inhibitor of the recombinant human isoforms, particularly when used at 1 mM final concentration. No apparent differences between the two isoforms were found.

**Example 8b: ELMIRON™ Assay:**

ELMIRON™ (Alza, Mountain View, California) is a drug that lessens the symptomology of inflammation in the bladder and

gastrointestinal tract (GI). It is believed that tryptase mediates a great deal of inflammation in the bladder and the GI. Thus, ELMIRON™ was tested for its direct effect on the enzymatic inhibition of recombinant  $\beta$ -II tryptase generated from pPIC9-HumTryN102K by titrating the drug on tryptase.

5  $\beta$ -II tryptase was diluted into 20  $\mu$ g per ml fractions in 10 mM MES, 0.2 M NaCl, and 0.5 mg/ml heparin, pH 6.1, in 10 full dilutions of ELMIRON™ (suspended in water pH 6.0 at a stock concentration of 50 mg/ml). Various concentrations (25, 2.5, 0.25 and 0.025 mg/ml) were incubated with the  $\beta$ -II tryptase for 3 hours. Activity was assayed by CBZ-  
10 Lys-Thiobenzl Ester/ DNTB coupled cleavage. It was found that ELMIRON™ did not inhibit  $\beta$ -II tryptase at the tested concentration range of 25 to 0.025 mg/ml.

#### Fibrinogen Cleavage Assay

##### **Example 9: The Fibrinolytic Activity of Recombinant and Native $\beta$ - tryptases:**

Referring to Fig. 9, purified native and recombinant  $\beta$ -tryptases were evaluated for their capacity to metabolize human fibrinogen as described by Schwartz et al. (1985). Lyophilized fibrinogen was resuspended at a concentration of 1.0 mg/ml in 10mM Tris, pH 7.4, containing 10mM CaCl<sub>2</sub> and 150mM NaCl with 0.5 mg/ml heparin. The fibrinogen master mix was divided into four 100ml aliquots and either 5  $\mu$ g recombinant  $\beta$ -I tryptase (R  $\beta$ I tryptase), recombinant  $\beta$ -II tryptase (R  $\beta$ II tryptase), or native  $\beta$ -tryptase (Native  $\beta$ ) was added to one of three tubes. The remaining tube served as a control (no enzyme). The tubes containing the tryptase and fibrinogen were further divided into two tubes with one incubated at -20°C and the other at 37°C for a period of 60 minutes. The reactions were then  
25 analyzed by loading 2  $\mu$ g equivalents of protein on a 4-20% Tris Glycine

SDS-PAGE gel by standard electrophoretic methods. The gel was stained by Gel Code, dried, and imaged by scanning.

As Fig. 9 shows, the fibrinogen  $\alpha$ ,  $\beta$ ,  $\gamma$  subunits were not degraded in the absence of tryptase enzyme with either incubation treatment. The  $\alpha$  and  $\beta$  subunits were efficiently hydrolyzed by the recombinant  $\beta$ -I and  $\beta$ -II tryptase enzymes even during cold incubation. Native  $\beta$ -tryptase was less efficient at fibrinogeneolysis, but this was expected due to overall lower specific activity with synthetic substrates in comparison to the recombinant enzymes.

It is understood that the recombinant human tryptase and the methods to obtain the recombinant human tryptase are not confined to the particular reagents, host organisms, and genetic manipulations expressly illustrated and described herein, but embrace all modified and equivalent forms thereof as come within the scope of the attached claims.

## BIBLIOGRAPHY

- Blom, T. and Hellman, L. (1993), *Scand. J. Immunol.* 37:203-208.
- Buckholz, R.G. and Gleeson, M.A.G. (1991), *Biotechnology* 9:1067-1072.
- Chan, H.; Elrod, K.C.; Numerof, R.P. Sideris, S; and Clark, J.M. (1999), *Protein Express. & Purif.* 15:251-257.
- Clark J.M.; Abraham, W.M.; Fishman, C.E.; Foreza, R. Ahmed, A.; Cortes, A.; Warne, R.L.; Moore, W.R; and Tanaka, R.D. (1995), *Am. J. Respir. Crit. Care Med.* 152:2076-2083.
- Holgate S.T. and Church, M.K. (1992), *Br. Med. Bull UK* 48:40-50.
- Huang C.; Li, L.; Krilis, S.A.; Chanasyk, K.; Tang, Y.; Li, Z.; Hunt, J.E.; and Stevens, R.L. (1999), *J. Biol. Chem.* 274:19670-19676.
- Faber K.N.; Harder, W.; Ab, G.; and Veenhuis, M. (1995), *Yeast* 11:1331-1344.
- Harvima, I.T.; Schechter N.M.; Harvima, R.J.; and Fräki, J.E. (1988) Human Skin Tryptase: Purification, Partial Characterization and Comparison with Human Lung Tryptase, *Biochimica et Biophysica Acta*, 957:71-80.
- Huang, C.; Li, L.; Krilis, S.A.; Chanasyk, K.; Tang, Y.; Li, Z.; Hunt, J.E.; and Stevens, R.L. (1999) Human Tryptase  $\alpha$  and  $\beta$ /II are Functionally Distinct Due, in Part, to a Single Amino Acid Difference in One of the Surface Loops that Forms the Substrate-binding Cleft, *J. Biol. Chem.* 274:19670-19676.
- Huang, C.; Guillermo, M.; Vagi, A.; Chanasyk, K.; Ferrazzi, M.; Burklow, C.; Qiu, W.; Feyfant, E.; Sali, A.; and Stevens, R.L. , (2000) Formation of Enzymatically Active, Homotypic, and Heterotypic Tetramers of Mouse Mast Cell Tryptases, *J. Biol. Chem.* 275:351-358.

Ide, H.; Itoh, H.; Tomita, M.; Murakumo, Y.; Kobayashi, T.; Maruyama, H.; Osada, Y.; and Nawa, Y. (1995), *J. Biochem.* 118:210-215.

Miller, J.S.; Moxley, G.; and Schwartz, L.B. (1990), *J. Clin. Invest.* 86:864-870.

Niles, A.L.; Maffitt, M.; Haak-Frendscho, M.; Wheelless, C.J.; and Johnson, D.A. (1998), Recombinant Human Mast Cell Tryptase: Stable Expression in *Pichia pastoris* and Purification of Fully Active Enzyme, *Biotechnol. Appl. Biochem.* 28:125-131.

Nilsson and Schwartz (1994), Mast-Cell Heterogeneity: Structure and Mediators, Blackwell Scientific Publications, Boston, pp. 195-208.

Pallaoro, M.; Fejzo, M.S.; Shayesteh, L.; Blount, J.L.; and Caughey, G.H. (1999), Characterization of Genes Encoding Known and Novel Human Mast Cell Tryptases on Chromosome 16p13.3, *J. Biol. Chem.* 6:3355-3362.

Sakai K.; Long, S.D.; Dove-Pettit, D.A.; Cabral, G.A.; and Schwartz, L.B. (1996), *Protein Express. & Purif.* 7:67-73.

Sambrook, J.; Fritsch, E. F.; and Maniatis, T. (1989), *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: New York, NY.

Schwartz L.B.; Bradford, T.R.; Littman, B.H.; and Wintroub, B.U. (1985), *J. Immun.* 135:2762-2767.

Schwartz L and Bradford T. (1986) Regulation of tryptase from human lung mast cells by heparin: Stabilization of the active tetramer, *J. Biol. Chem.* 256: 7372-7379.

Schwartz (1995), Structure and Function of Human Mast Cell Tryptase, Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function, chapter 14:161-173, Raven Press, Ltd: New York.

